CCM
NBIX icon

Condor Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Condor Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$843K Buy
6,398
+104
+2% +$13.8K 0.07% 124
2025
Q4 		$893K Sell
6,294
-14
-0.2% -$2.03K 0.07% 127
2025
Q3 		$886K Hold
6,308
– – 0.07% 131
2025
Q2 		$793K Buy
6,308
+67
+1% +$7.68K 0.07% 133
2025
Q1 		$690K Buy
+6,241
New +$791K 0.06% 138

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Condor Capital Management's NBIX Position: Q1 2026 in Review

Condor Capital Management increased its Neurocrine Biosciences (NBIX) stake by 1.7% in Q1 2026, buying an estimated $13.8K and bringing the position to 6,398 shares worth $843K. The position accounts for 0.07% of the portfolio, ranked #124.

Condor Capital Management first reported a position in NBIX in Q1 2025 and has held it in 5 quarters since. The position peaked at $893K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Condor Capital Management held 6,398 shares of Neurocrine Biosciences worth $843K as of Q1 2026.
  • Condor Capital Management bought 104 Neurocrine Biosciences shares in Q1 2026, an estimated $13.8K.
  • Neurocrine Biosciences made up 0.07% of Condor Capital Management's portfolio in Q1 2026, its #124 holding.
  • Condor Capital Management first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 5 quarters since.
  • Condor Capital Management's Neurocrine Biosciences position peaked at $893K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Condor Capital Management's 13F filing for Q1 2026, filed 11 May 2026.